Xilio Therapeutics (XLO) Competitors $0.71 0.00 (-0.34%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$0.73 +0.02 (+3.09%) As of 08:25 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock XLO vs. CTNM, RAPT, TNGX, TARA, ACTU, LYEL, GLSI, IKT, PRQR, and FDMTShould you be buying Xilio Therapeutics stock or one of its competitors? The main competitors of Xilio Therapeutics include Contineum Therapeutics (CTNM), RAPT Therapeutics (RAPT), Tango Therapeutics (TNGX), Protara Therapeutics (TARA), Actuate Therapeutics (ACTU), Lyell Immunopharma (LYEL), Greenwich LifeSciences (GLSI), Inhibikase Therapeutics (IKT), ProQR Therapeutics (PRQR), and 4D Molecular Therapeutics (FDMT). These companies are all part of the "pharmaceutical products" industry. Xilio Therapeutics vs. Contineum Therapeutics RAPT Therapeutics Tango Therapeutics Protara Therapeutics Actuate Therapeutics Lyell Immunopharma Greenwich LifeSciences Inhibikase Therapeutics ProQR Therapeutics 4D Molecular Therapeutics Xilio Therapeutics (NASDAQ:XLO) and Contineum Therapeutics (NASDAQ:CTNM) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, community ranking, risk, institutional ownership and media sentiment. Do institutionals & insiders hold more shares of XLO or CTNM? 54.3% of Xilio Therapeutics shares are held by institutional investors. 5.2% of Xilio Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media refer more to XLO or CTNM? In the previous week, Contineum Therapeutics had 5 more articles in the media than Xilio Therapeutics. MarketBeat recorded 6 mentions for Contineum Therapeutics and 1 mentions for Xilio Therapeutics. Xilio Therapeutics' average media sentiment score of 1.87 beat Contineum Therapeutics' score of 0.70 indicating that Xilio Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Xilio Therapeutics Very Positive Contineum Therapeutics Positive Does the MarketBeat Community prefer XLO or CTNM? Xilio Therapeutics received 1 more outperform votes than Contineum Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Contineum Therapeutics an outperform vote while only 75.00% of users gave Xilio Therapeutics an outperform vote. CompanyUnderperformOutperformXilio TherapeuticsOutperform Votes1275.00% Underperform Votes425.00% Contineum TherapeuticsOutperform Votes11100.00% Underperform VotesNo Votes Which has better valuation & earnings, XLO or CTNM? Contineum Therapeutics has higher revenue and earnings than Xilio Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Xilio Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXilio Therapeutics$6.34M5.81-$76.40M-$1.28-0.56Contineum Therapeutics$50M2.13$22.72M-$4.90-0.84 Do analysts recommend XLO or CTNM? Xilio Therapeutics presently has a consensus target price of $4.00, suggesting a potential upside of 461.80%. Contineum Therapeutics has a consensus target price of $24.80, suggesting a potential upside of 503.41%. Given Contineum Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Contineum Therapeutics is more favorable than Xilio Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xilio Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Contineum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Is XLO or CTNM more profitable? Contineum Therapeutics' return on equity of -49.92% beat Xilio Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Xilio TherapeuticsN/A -211.50% -80.31% Contineum Therapeutics N/A -49.92%-20.52% SummaryContineum Therapeutics beats Xilio Therapeutics on 10 of the 17 factors compared between the two stocks. Remove Ads Get Xilio Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for XLO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XLO vs. The Competition Export to ExcelMetricXilio TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$36.86M$6.33B$5.33B$7.57BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-0.416.8121.7017.82Price / Sales5.81225.96377.7294.61Price / CashN/A65.6738.1534.64Price / Book0.535.866.464.00Net Income-$76.40M$141.86M$3.20B$247.23M7 Day Performance4.71%4.38%2.77%1.44%1 Month Performance-11.02%-12.76%-8.60%-6.26%1 Year Performance-45.23%-11.13%10.40%0.59% Xilio Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XLOXilio Therapeutics2.7958 of 5 stars$0.71-0.3%$4.00+461.8%-43.5%$36.86M$6.34M-0.4170Gap DownCTNMContineum Therapeutics2.166 of 5 stars$5.37-7.4%$24.80+361.8%-71.9%$138.93M$50M-1.1031News CoveragePositive NewsGap DownRAPTRAPT Therapeutics3.6395 of 5 stars$1.05-0.9%$4.00+281.0%-90.0%$138.61M$1.53M-0.3880Short Interest ↑News CoverageGap DownTNGXTango Therapeutics1.9315 of 5 stars$1.27flat$12.33+871.1%-81.2%$137.30M$42.07M-1.0890Analyst ForecastAnalyst RevisionNews CoverageTARAProtara Therapeutics1.9947 of 5 stars$3.70-5.1%$22.50+508.1%+46.8%$136.04MN/A-1.3130Analyst ForecastNews CoverageACTUActuate TherapeuticsN/A$6.82-1.0%$20.00+193.3%N/A$133.21MN/A0.0010LYELLyell Immunopharma3.2259 of 5 stars$0.45-3.9%$1.00+123.9%-80.9%$131.85M$61,000.00-0.57270Analyst ForecastNews CoverageGLSIGreenwich LifeSciences1.9672 of 5 stars$9.59+8.6%$38.00+296.2%-37.2%$126.06MN/A-11.993Earnings ReportUpcoming EarningsNews CoverageHigh Trading VolumeIKTInhibikase Therapeutics1.4363 of 5 stars$1.68-8.7%$6.50+286.9%-13.4%$124.90M$260,000.00-0.636Gap DownPRQRProQR Therapeutics2.169 of 5 stars$1.17-0.8%$9.50+712.0%-41.8%$123.10M$18.91M-3.66180Short Interest ↓News CoverageFDMT4D Molecular Therapeutics2.5766 of 5 stars$2.65-4.3%$26.71+908.1%-88.2%$122.70M$37,000.00-0.93120Positive NewsGap Down Remove Ads Related Companies and Tools Related Companies CTNM Competitors RAPT Competitors TNGX Competitors TARA Competitors ACTU Competitors LYEL Competitors GLSI Competitors IKT Competitors PRQR Competitors FDMT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XLO) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredMusk's panic move: What the world's richest man fears is comingWhether you have modest savings of $10,000 or substantial wealth of $10 million, this information could determ...InvestorPlace | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xilio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xilio Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy XLO Stock Free XLO Stock Alerts